Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024 ...

Researchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune ...

After reviewing several large epidemiological studies, clinical trial and in-market data, EMA’s Pharmacovigilance Risk Assessment Committee has concluded non-anterior ischemic optic neuropathy is a ...

Turning the human body into a biofactory of precision protein therapeutics is the focus of newly launched Signify Bio, which ...

As it advances its nonopioid analgesic ATX-101 breakthrough therapy through a phase IIb registration trial, Allay Therapeutics secured $57.5 million in a series D round, which included an investment ...

The U.S. FDA posted notice of six class I device recalls between June 3 and June 5, 2025, four of which are for corrections.

A publication based on longitudinal and cross sectional data and led by researchers at the U.S. NIH’s National Institute on ...

Solvonis Therapeutics plc has completed synthesis of development candidates for its SVN-SDN-014 program, a novel series of serotonin, dopamine and noradrenaline modulators.

Mindimmune Therapeutics Inc. has been awarded a grant by Rhode Island Life Science Hub to accelerate preclinical development work on MITI-101 for the treatment of mild to moderate Alzheimer’s disease.

Merck Sharp & Dohme LLC has identified compounds acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) and/or 2 (HCN2) blockers reported to be useful for the ...